Biotech: Page 2
-
SponsoredShifting the biomanufacturing paradigm - intensifying upstream processes
Game-changing technologies to intensify upstream processes.
-
Aveo's cancer drug runs into a skeptical FDA
The regulator told the Cambridge, Massachusetts-based biotech to hold off on filing its cancer drug, sending shares in the company down 40%.
By Andrew Dunn • Nov. 04, 2019 -
China approves Alzheimer's drug, inviting fresh debate in field with few successes
Developed by a little-known Shanghai drugmaker, the therapy joins a short list of approved Alzheimer's treatments. Yet how well it works is an open question.
By Ned Pagliarulo • UPDATED: Nov. 4, 2019 at 3:09 p.m. -
Amgen exits neuroscience R&D as pharma pulls back from field
About 180 roles, primarily based in Cambridge, Massachusetts, will be affected by the decision, which comes several months after a setback in Alzheimer's.
By Andrew Dunn • Oct. 30, 2019 -
CF Foundation puts half a billion dollars toward drugs for all patients
About 90% of cystic fibrosis patients can take one of Vertex's drugs. The remaining 10% have no options — something the foundation wants to change.
By Jacob Bell • Oct. 30, 2019 -
Mirati keeps pace with Amgen in hunt for KRAS cancer drug
Initial trial results showed Mirati's closely watched KRAS inhibitor led to responses in patients with lung and colon cancers, although data remain early.
By Ned Pagliarulo • Oct. 28, 2019 -
ColumnPharmacquired: Eylea could be in trouble, but that doesn't make Regeneron a buyer
A rival medicine from Novartis and potential changes to Medicare aren't likely enough for Regeneron to reverse its decades-long aversion to M&A.
By Jacob Bell • Oct. 25, 2019 -
Rubius' roller coaster ride set to accelerate with first clinical results
Since an IPO last July, shares in the platform biotech have fallen by nearly two-thirds. Can the first glimpse at clinical results, expected soon, spur a rebound?
By Andrew Dunn • Oct. 24, 2019 -
With massive debt looming, Acorda to lay off about 120 in restructuring
Even with the cost-cutting, Wall Street analysts still raised concerns over the biotech's liabilities, with $345 million in debt coming due in 2021.
By Andrew Dunn • Oct. 24, 2019 -
Vertex clears its biggest commercial hurdle: UK insurance coverage
After months of testy negotiations, Vertex and English health authorities have created a reimbursement plan for the company's cystic fibrosis drugs.
By Jacob Bell • Oct. 24, 2019 -
Alkermes to lay off 160 in cost-cutting restructure
Shares have fallen by more than a third since the start of 2019, a slide the company hopes to correct with plans to cut costs and curtail future hiring.
By Kristin Jensen • Oct. 23, 2019 -
In major surprise, Biogen will ask FDA to approve Alzheimer's drug aducanumab
New data from two trials halted earlier this year found the drug reduced clinical decline, Biogen said in an announcement likely to reverberate throughout the Alzheimer's research community.
By Jacob Bell • Oct. 22, 2019 -
Vertex wins speedy approval for cystic fibrosis triplet
With Trikafta cleared by the Food and Drug Administration, Vertex estimates its drugs can treat as much as 90% of patients with the lung condition.
By Jacob Bell • Oct. 21, 2019 -
Seattle Genetics stock hits record high on well-placed breast cancer bet
Positive results for tucatinib should help the Seattle biotech in its quest to expand beyond Adcetris, currently its only approved drug.
By Ned Pagliarulo • Oct. 21, 2019 -
Mirati data to test whether biotech can challenge Amgen in KRAS quest
Shares in Mirati soared this year, driven higher by optimism the drugmaker can replicate Amgen's KRAS success. Data due Oct. 28 will give the first look at whether Mirati's candidate holds promise.
By Ned Pagliarulo • Oct. 18, 2019 -
Reata surprises with positive data in challenging rare disease
There are no FDA-approved drugs for Friedreich's Ataxia, an uncommon neurological disorder. Reata looks closer to changing that with its latest data.
By Jacob Bell • Oct. 15, 2019 -
Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field
Newly launched as Ichnos, the spin-out company is led by former Gilead oncology chief Alessandro Riva.
By Ned Pagliarulo • Oct. 15, 2019 -
Pelosi drug plan would save $370B, but could reduce R&D, forecasters say
Pharma would respond to Pelosi's proposal by raising list prices, keeping some drugs off foreign markets, and cutting R&D spending, according to the CBO.
By Jonathan Gardner • Oct. 14, 2019 -
Revance CEO stepping down over 'misjudgment'
Dan Browne, who has led Revance for the past 17 years, will be replaced by board member and former Zeltiq CEO Mark Foley.
By Ned Pagliarulo • Oct. 14, 2019 -
Five Prime's restructuring claims more jobs
Roughly 70 jobs will be eliminated, leaving a "small research group" to develop the California biotech's three wholly-owned drugs.
By Jacob Bell • Oct. 11, 2019 -
Gene therapy biotechs caught in manufacturing crunch
Rising demand for contract manufacturing services could push companies to invest more in their own capabilities despite the high cost.
By Ned Pagliarulo • UPDATED: Oct. 11, 2019 at 10:49 a.m. -
Reata buys drug rights back from AbbVie for $330M before readout
"It shows our confidence, but we'll have to see how the data plays out," the biotech's CFO told BioPharma Dive.
By Andrew Dunn • Oct. 10, 2019 -
Arbutus stops early hepatitis B study on safety concerns
Shares in the Pennsylvania biotech shed a quarter of their value Friday, putting the company down more than 70% for the year.
By Ned Pagliarulo • Oct. 04, 2019 -
Gilead's follow-on PrEP drug gets broad label, but with a notable exclusion
The FDA approved Descovy to prevent HIV infection in adults and adolescents, but not for cisgender women.
By Jacob Bell • Oct. 04, 2019 -
Gene therapy stocks have taken a beating. Their recovery may be slow
Share prices of at least 26 gene therapy biotechs are down from last October, a sign that investors may want more clarity on how the drugs will be sold.
By Jacob Bell • Oct. 03, 2019
Previous
